Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
NATHAN DOWDEN | Officer | Sep 06 '24 | Proposed Sale | 15.39 | 3,150 | 48,478 | | Sep 06 04:19 PM | Dowden Nathan J | President & COO | Aug 16 '24 | Option Exercise | 1.74 | 20,000 | 34,800 | 157,204 | Aug 20 04:33 PM | Dowden Nathan J | President & COO | Aug 16 '24 | Sale | 16.27 | 27,097 | 440,801 | 130,107 | Aug 20 04:33 PM | NATHAN DOWDEN | Officer | Aug 16 '24 | Proposed Sale | 16.26 | 27,097 | 440,597 | | Aug 16 04:25 PM | Sethuraman Natarajan | Chief Scientific Officer | Jul 15 '24 | Sale | 18.00 | 638 | 11,484 | 188,814 | Jul 16 04:43 PM | Sethuraman Natarajan | Chief Scientific Officer | Jul 12 '24 | Sale | 18.00 | 600 | 10,800 | 189,452 | Jul 16 04:43 PM | Doshi Dipal | CEO | Jul 15 '24 | Sale | 17.81 | 1,600 | 28,497 | 334,475 | Jul 16 04:42 PM | Doshi Dipal | CEO | Jul 12 '24 | Sale | 18.00 | 300 | 5,400 | 336,075 | Jul 16 04:42 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Jul 08 '24 | Sale | 14.95 | 1,758 | 26,282 | 81,412 | Jul 10 04:34 PM | Doshi Dipal | CEO | Jun 13 '24 | Sale | 16.17 | 1,000 | 16,174 | 336,375 | Jun 14 04:32 PM | KIM PETER S | Director | Jun 03 '24 | Option Exercise | 6.06 | 11,918 | 72,223 | 104,330 | Jun 05 04:31 PM | Sethuraman Natarajan | Chief Scientific Officer | May 20 '24 | Sale | 15.19 | 9,675 | 146,944 | 190,052 | May 20 05:26 PM | Sethuraman Natarajan | Chief Scientific Officer | May 17 '24 | Sale | 15.14 | 8,305 | 125,751 | 199,727 | May 20 05:26 PM | Sethuraman Natarajan | Chief Scientific Officer | May 16 '24 | Sale | 15.00 | 1,000 | 15,000 | 208,032 | May 20 05:26 PM | Doshi Dipal | CEO | May 16 '24 | Sale | 15.00 | 1,800 | 27,000 | 338,575 | May 20 05:21 PM | Doshi Dipal | CEO | May 17 '24 | Sale | 15.11 | 1,200 | 18,129 | 337,375 | May 20 05:21 PM | KIM PETER S | Director | May 14 '24 | Buy | 14.59 | 25,000 | 364,672 | 92,412 | May 16 04:33 PM | KIM PETER S | Director | May 08 '24 | Buy | 14.04 | 2,276 | 31,965 | 65,212 | May 10 04:35 PM | KIM PETER S | Director | May 09 '24 | Buy | 14.25 | 2,200 | 31,341 | 67,412 | May 10 04:35 PM | KIM PETER S | Director | Apr 08 '24 | Buy | 13.57 | 2,600 | 35,290 | 62,936 | Apr 10 04:35 PM | KIM PETER S | Director | Mar 28 '24 | Buy | 13.75 | 1,512 | 20,794 | 60,336 | Apr 01 04:31 PM | KIM PETER S | Director | Mar 22 '24 | Buy | 13.76 | 3,118 | 42,901 | 52,894 | Mar 26 05:57 PM | KIM PETER S | Director | Mar 25 '24 | Buy | 13.36 | 3,180 | 42,472 | 56,074 | Mar 26 05:57 PM | KIM PETER S | Director | Mar 26 '24 | Buy | 13.64 | 2,750 | 37,509 | 58,824 | Mar 26 05:57 PM | KIM PETER S | Director | Mar 20 '24 | Buy | 12.66 | 1,128 | 14,281 | 49,072 | Mar 21 04:31 PM | KIM PETER S | Director | Mar 19 '24 | Buy | 12.66 | 900 | 11,397 | 47,944 | Mar 21 04:31 PM | KIM PETER S | Director | Mar 21 '24 | Buy | 13.24 | 704 | 9,318 | 49,776 | Mar 21 04:31 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Mar 15 '24 | Option Exercise | 2.10 | 9,000 | 18,900 | 83,170 | Mar 19 04:33 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Mar 06 '24 | Sale | 12.31 | 4,086 | 50,285 | 74,170 | Mar 08 04:36 PM | Dowden Nathan J | President & COO | Mar 06 '24 | Sale | 12.32 | 1,826 | 22,499 | 137,204 | Mar 08 04:34 PM | Doshi Dipal | CEO | Feb 15 '24 | Sale | 15.00 | 1,000 | 15,000 | 243,279 | Feb 20 04:37 PM | Doshi Dipal | CEO | Jan 16 '24 | Sale | 15.99 | 1,000 | 15,990 | 244,279 | Jan 18 04:32 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 22 '23 | Option Exercise | 2.10 | 10,206 | 21,433 | 59,777 | Dec 26 04:35 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 21 '23 | Option Exercise | 2.10 | 2,200 | 4,620 | 51,771 | Dec 26 04:35 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 26 '23 | Option Exercise | 2.10 | 94 | 197 | 49,665 | Dec 26 04:35 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 22 '23 | Sale | 15.69 | 10,206 | 160,124 | 49,571 | Dec 26 04:35 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 21 '23 | Sale | 15.07 | 2,200 | 33,155 | 49,571 | Dec 26 04:35 PM | WENTWORTH KORY JAMES | Chief Financial Officer | Dec 26 '23 | Sale | 16.67 | 94 | 1,567 | 49,571 | Dec 26 04:35 PM | Doshi Dipal | President and CEO | Dec 20 '23 | Sale | 15.00 | 1,000 | 15,000 | 245,279 | Dec 22 04:38 PM | Doshi Dipal | President and CEO | Nov 13 '23 | Sale | 16.23 | 1,000 | 16,230 | 246,279 | Nov 13 04:35 PM | Doshi Dipal | President and CEO | Oct 17 '23 | Sale | 15.00 | 1,000 | 15,000 | 247,279 | Oct 19 05:27 PM | Doshi Dipal | President and CEO | Sep 13 '23 | Sale | 15.00 | 1,000 | 15,000 | 248,279 | Sep 15 04:21 PM |
|